"The agreement with Roche Diabetes Care represents a culmination of our development efforts to date," explains Peter Kirschbauer, CEO of ICW AG. "Roche Diabetes Care will leverage the ICW eHealth Framework and our successful deployment of the highest security standards for information exchange, as we co-develop new and advanced approaches to sharing relevant diabetes data. We are very pleased to have Roche Diabetes Care as our partner."
About InterComponentWareInterComponentWare AG (ICW) is a leading international eHealth specialist with locations in Germany, Austria, Switzerland and the USA. ICW delivers an interoperable eHealth infrastructure and a range of end-user applications for healthcare professionals and their patients. ICW technology enables organizations to extend their existing information systems, connect with diverse systems, and create a secure patient health record based on aggregated data. ICW has successfully implemented its solutions across Europe and in North America.
Visit online at www.icw-global.com.
About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chug
|SOURCE InterComponentWare AG|
Copyright©2010 PR Newswire.
All rights reserved